JPH041728B2 - - Google Patents

Info

Publication number
JPH041728B2
JPH041728B2 JP62092947A JP9294787A JPH041728B2 JP H041728 B2 JPH041728 B2 JP H041728B2 JP 62092947 A JP62092947 A JP 62092947A JP 9294787 A JP9294787 A JP 9294787A JP H041728 B2 JPH041728 B2 JP H041728B2
Authority
JP
Japan
Prior art keywords
adjuvant
oil
purified
antigen
detoxified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62092947A
Other languages
English (en)
Japanese (ja)
Other versions
JPS6310736A (ja
Inventor
Eru Kantoreru Jon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of JPS6310736A publication Critical patent/JPS6310736A/ja
Publication of JPH041728B2 publication Critical patent/JPH041728B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP62092947A 1986-04-15 1987-04-15 免疫学的アジュバント Granted JPS6310736A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/852,120 US4806352A (en) 1986-04-15 1986-04-15 Immunological lipid emulsion adjuvant
US852120 1986-04-15

Publications (2)

Publication Number Publication Date
JPS6310736A JPS6310736A (ja) 1988-01-18
JPH041728B2 true JPH041728B2 (enExample) 1992-01-14

Family

ID=25312542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62092947A Granted JPS6310736A (ja) 1986-04-15 1987-04-15 免疫学的アジュバント

Country Status (9)

Country Link
US (1) US4806352A (enExample)
JP (1) JPS6310736A (enExample)
AU (1) AU574014B2 (enExample)
CA (1) CA1300503C (enExample)
DE (1) DE3712767A1 (enExample)
ES (1) ES2005166A6 (enExample)
FR (2) FR2596990B1 (enExample)
GB (1) GB2189141B (enExample)
IT (1) IT1205819B (enExample)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
DE3601136A1 (de) * 1986-01-16 1987-07-23 Max Planck Gesellschaft Hemmstoffe der reversen transkriptase fuer prophylaxe und therapie von retrovirus-infektionen in saeugetieren
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
US5466714A (en) * 1987-12-31 1995-11-14 Research Foundation For Mental Health Hygiene, Inc. Spermicidal and cytocidal fatty acid compositions
US5434182A (en) * 1987-12-31 1995-07-18 Isaacs; Charles E. Antibacterial fatty acid compositions
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
EP0324455A3 (en) * 1988-01-15 1991-03-27 Hans O. Ribi Novel polymeric immunological adjuvants
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
FI902821A7 (fi) * 1989-06-12 1990-12-13 Res Foundation For Mental Hygiene Infektion leviämisen vähentäminen verenkäsittelylaitteistolla
DE4007315A1 (de) * 1990-03-08 1991-09-12 Behringwerke Ag Verwendung von zink-calciumhydroxid, lecithin und pao zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
CA2106474C (en) 1991-03-19 2004-02-10 R. Martin Emanuele Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
US5688761A (en) * 1991-04-19 1997-11-18 Lds Technologies, Inc. Convertible microemulsion formulations
JPH06507172A (ja) * 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド 転換可能なミクロエマルジョン処方剤
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
EP0702563B1 (en) * 1993-05-27 2003-08-06 EntreMed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
KR100508910B1 (ko) 1995-10-17 2006-04-20 알티피 파마 코포레이션 불용성약물방출
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US5849307A (en) * 1997-03-26 1998-12-15 The Picower Institute For Medical Research Vaccine adjuvant
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
CN1289091C (zh) * 1998-02-11 2006-12-13 Rtp药品公司 治疗炎症的药物组合物和相关用途
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
KR100635456B1 (ko) 1998-05-29 2006-10-18 스키에파마 캐나다 인코포레이티드 열보호화 마이크로입자 조성물 및 그의 말단의 스팀멸균방법
EP1105096B1 (en) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
KR20010073232A (ko) * 1998-11-20 2001-07-31 추후제출 분산성 인지질로 안정화된 마이크로입자
EP2281834B1 (en) 1999-04-09 2015-03-04 Zoetis P&U LLC Attenuated Pasteurellaceae bacterium having a mutation in a virulence gene
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
JP2003509453A (ja) * 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
WO2001070247A2 (en) 2000-03-17 2001-09-27 Pharmacia & Upjohn Company Salmonella vaccine materials and methods
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
HK1053786A1 (zh) 2000-04-20 2003-11-07 Rtp Pharma Inc. 改进的水不溶的药物颗粒工艺
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
ES2325057T3 (es) 2000-08-31 2009-08-25 Jagotec Ag Particulas molturadas.
JP2004509146A (ja) * 2000-09-20 2004-03-25 スカイファーマ・カナダ・インコーポレーテッド 安定化フィブレート微粒子
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
PL202778B1 (pl) * 2001-02-22 2009-07-31 Skyepharma Canada Inc Postać dawkowana kombinacji statyny i fenofibratu, sposób jej wytwarzania i zastosowanie
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
EP1594524B1 (en) 2003-01-21 2012-08-15 Novartis Vaccines and Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
EP2258365B1 (en) 2003-03-28 2013-05-29 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
ES2388556T3 (es) * 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
AU2008303023B2 (en) 2007-09-27 2014-01-09 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
EP2529641B1 (en) 2010-01-29 2015-11-11 Kabushiki Kaisha Mikimoto Clasp for accessory
KR102230562B1 (ko) 2010-05-14 2021-03-22 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
JP2014500267A (ja) 2010-12-08 2014-01-09 ネオヴァクス 強力に不活性化されているがなお高い免疫原性を示すワクチンおよびその製造方法
JP6335778B2 (ja) 2011-04-07 2018-05-30 ネオヴァクス Ｉｆｎアルファ関連疾病の処置方法
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
US10105435B2 (en) 2011-10-06 2018-10-23 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
KR20150038380A (ko) 2012-07-27 2015-04-08 백스터 인터내셔널 인코포레이티드 키메라 ospa 분자를 포함하는 조성물 및 이의 사용 방법
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EA201790558A1 (ru) 2014-10-15 2017-08-31 Ксенотера Композиция с пониженной иммуногенностью
TW202015725A (zh) 2018-06-04 2020-05-01 美商亞博創新醫藥有限公司 Tlr7 肽結合物
AU2019297321B2 (en) 2018-07-02 2022-02-03 Ayuvis Research, Inc. Novel immunodulating small molecules
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
GB202009411D0 (en) 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
CN112807426A (zh) * 2021-01-26 2021-05-18 郭志文 一种基于动物疫苗的聚合物佐剂、制备方法及其应用
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023036814A1 (en) 2021-09-07 2023-03-16 Universite De Tours Coronavirus fusion protein
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
CA943459A (en) * 1968-12-16 1974-03-12 Abbott Laboratories Chemically modified endotoxin immunizing agent
FR2160326B1 (enExample) * 1971-11-19 1975-02-07 Anvar
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
GB1506563A (en) * 1974-04-25 1978-04-05 Williams J Immunosuppressive agents
FR2313078A1 (fr) * 1975-02-07 1976-12-31 Anvar Composition a base d'huile vegetale metabolisable et d'eau, utilisable notamment pour la constitution de preparations adjuvantes, ces preparations adjuvantes et leur procede d'obtention
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
CA1225592A (en) * 1983-08-26 1987-08-18 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
JPH077201B2 (ja) * 1985-10-19 1995-01-30 富士写真フイルム株式会社 ハロゲン化銀カラ−写真感光材料の処理方法

Also Published As

Publication number Publication date
GB2189141B (en) 1990-07-25
CA1300503C (en) 1992-05-12
AU7156687A (en) 1987-10-22
US4806352A (en) 1989-02-21
IT8747855A0 (it) 1987-04-15
JPS6310736A (ja) 1988-01-18
DE3712767C2 (enExample) 1991-06-27
FR2596990A1 (fr) 1987-10-16
GB8709023D0 (en) 1987-05-20
FR2598622A1 (fr) 1987-11-20
ES2005166A6 (es) 1989-03-01
IT1205819B (it) 1989-03-31
AU574014B2 (en) 1988-06-23
GB2189141A (en) 1987-10-21
FR2596990B1 (fr) 1990-12-07
DE3712767A1 (de) 1987-10-22
FR2598622B1 (fr) 1990-05-11

Similar Documents

Publication Publication Date Title
JPH041728B2 (enExample)
JP2648305B2 (ja) 多糖類ワクチン
JP3814290B2 (ja) 抗原用のアジュバントおよびその製法ならびに用途
JP5019494B2 (ja) モノホスホリルリピドａの水性免疫アジュバント組成物
JP5075317B2 (ja) 莢膜性多糖類の可溶化および組合せワクチン
JP2515321B2 (ja) ワクチン処方
DE60015084T2 (de) Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
AU710499B2 (en) Adjuvants for viral vaccines
JP2003502388A5 (enExample)
JP2002513773A (ja) アジュバント組成物及びその使用法
JP2003502388A (ja) モノホスホリルリピドａの水性免疫学的アジュバント組成物
JPH08325163A (ja) 哺乳動物用ワクチン組成物
US4395394A (en) Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
Harrison et al. Duration of immunity, efficacy and safety in sheep of a recombinant Taenia ovis vaccine formulated with saponin or selected adjuvants
US4310550A (en) Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
Edelman An overview of adjuvant use
Johansson et al. Identification of adjuvants that enhance the therapeutic antibody response to host IgE
AU615016B2 (en) Immunological adjuvent and process for preparing the same, pharmaceutical compositions, and process
JP2000504350A (ja) キトサン誘導性免疫強化
CN1226173A (zh) 脱乙酰壳多糖引起的免疫强化
JPS63258443A (ja) 新規アルキルアルカノエートおよびその製法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080114

Year of fee payment: 16